CG
Publications
190
Views
97,237
Downloads
28,682
Supervised works
11
1 - 190 of 190
Title Published in Access level OA Policy Year Views Downloads
Interleukin-18 binding protein deficiency results in gut microbiota dysbiosis and aggravated diet-induced MASH in miceJHEP reports
2026 29 15
Interleukin‐18 Binding Protein (IL‐18BP) Deficiency Affects Lymphocyte Activation and IL‐18 Expression in a Mouse Model of Liver InflammationEuropean Journal of Immunology
2025 107 179
Alerte au feu : des nanopompiers pour combattre les flammes de la polyarthrite rhumatoïdeRevue médicale suisse
2024 192 13
Anti-Apolipoprotein A-1 IgG, incident cardiovascular events and lipid paradox inrheumatoid arthritisESC (Europan Society of Cardiology) Congress 2024
2024 6 0
Anti-apolipoprotein A-1 IgG, incident cardiovascular events and lipid paradox in rheumatoid arthritis92nd EAS (European Atherosclerosis Society) Congress
2024 9 0
Rhumatologie en crise : repenser la formation et les soins face à un défi croissantRevue médicale suisse
2024 32 54
Anti-apolipoprotein A-1 IgG, incident cardiovascular events, and lipid paradox in rheumatoid arthritisFrontiers in cardiovascular medicine
2024 119 175
Prospective registration of trials : where we are, why, and how we could get betterJournal of clinical epidemiology
2024 56 216
Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studiesJoint bone spine
2024 101 116
IL-18 Binding Protein–Producing Cells Attenuate Anemia in Murine Macrophage Activation SyndromeThe Journal of immunology
2023 122 148
Impact of SARS-CoV2 infection on anti-apolipoprotein A-1 IgG response in inflammatory rheumatic diseasesFrontiers in immunology
2023 131 87
Reporting and Representativeness of Race, Ethnicity, and Socioeconomic Status in Systemic Sclerosis Randomized Trials: An Observational StudyArthritis care & research
2023 68 189
Special Issue “IL-1 family cytokines in host defense, inflammation and cancer”Cytokine
2022 209 236
Long-term persistence of antibodies after diphtheria/tetanus vaccination in immunosuppressed patients with inflammatory rheumatic diseases and healthy controlsVaccine
2022 67 0
Comparative Genetic Analysis of Psoriatic Arthritis and Psoriasis for the Discovery of Genetic Risk Factors and Risk Prediction ModelingArthritis & rheumatology
2022 133 138
Systemic effects of IL-6 blockade in rheumatoid arthritis beyond the jointsCytokine
2022 200 566
Predictive value of anti-CarP and anti-PAD3 antibodies alone or in combination with RF and ACPA on the severity of rheumatoid arthritisRheumatology
2021 379 476
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registriesRheumatology
2021 246 0
Discrimination of COVID-19 from inflammation-induced cytokine storm syndromes using disease-related blood biomarkersArthritis and Rheumatology
2021 197 275
Intracellular IL-1 receptor antagonist isoform 1 released from keratinocytes upon cell death acts as an inhibitor for the alarmin IL-1αJournal of Immunology
2020 365 2
Response to: 'When binary and continuous responses disagree' by Dr OuyangAnnals of the Rheumatic Diseases
2020 322 2
Evolving the comprehensive management of rheumatoid arthritis: identification of unmet needs and development of practical and educational toolsClinical and Experimental Rheumatology
2020 284 178
Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritisArthritis Research and Therapy
2020 415 437
IL-36 signaling in keratinocytes controls early IL-23 production in psoriasis-like dermatitisLife Science Alliance
2020 216 429
Individual therapeutic DAS28-d crit responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studiesRheumatology International
2020 250 131
Impact of acute inflammation on cytochromes P450 activity assessed by the Geneva CocktailClinical Pharmacology and Therapeutics
2020 337 569
Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbiditiesRMD Open
2020 140 65
IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndromeRheumatology
2020 276 0
Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trialThe Lancet
2020 307 0
The role of the IL-1 system in pregnancy and the use of IL-1 system markers to identify women at risk for pregnancy complications†Biology of Reproduction
2020 163 0
IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndromeRheumatology
2020 337 1
Production of IL-18 Binding Protein by Radiosensitive and Radioresistant Cells in CpG-Induced Macrophage Activation SyndromeJournal of Immunology
2020 285 1
Randomized clinical trials in ANCA-associated vasculitis: a systematic analysis of the WHO - International Clinical Trials Registry PlatformOrphanet Journal of Rare Diseases
2020 165 169
Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomesArthritis Research and Therapy
2020 195 135
Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in SwitzerlandRMD Open
2020 221 107
Detection of circulating highly expanded T-cell clones in at-risk individuals for rheumatoid arthritis before the clinical onset of the diseaseRheumatology
2020 331 9
Travel patterns, risk behaviour and health problems of travellers with rheumatic diseases compared to controls: A multi-centre, observational studyTravel Medicine and Infectious Disease
2020 168 0
Levels of CXCL13 and sICAM-1 correlate with disease activity score in patients with rheumatoid arthritis treated with tocilizumabAdvances in Rheumatology
2019 294 132
Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolutionRheumatology
2019 374 0
Safety and immunogenicity of tetanus/diphtheria vaccination in patients with rheumatic diseases-a prospective multi-centre cohort studyRheumatology
2019 310 0
The links of hepcidin and erythropoietin in the interplay of inflammation and iron deficiency in a large observational study of rheumatoid arthritisBritish Journal of Haematology
2019 259 0
Role of reproductive and menopausal factors in functional and structural progression of rheumatoid arthritis: results from the SCQM cohortRheumatology
2019 271 0
Long-term therapy with anakinra in hidradenitis suppurativa in three patientsInternational Journal of Dermatology
2019 331 1
Inadequate reporting of concomitant medications in rheumatology randomized controlled trials of pharmacologic interventionsSeminars in Arthritis and Rheumatism
2019 282 0
Ultrasound is not associated with the presence of systemic autoimmunity or symptoms in individuals at risk for rheumatoid arthritisRMD Open
2019 340 122
Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritisSeminars in Arthritis and Rheumatism
2019 321 239
Prevotella copri in individuals at risk for rheumatoid arthritisAnnals of the Rheumatic Diseases
2019 469 0
Variable domain N-linked glycosylation and negative surface charge are key features of monoclonal ACPA: Implications for B-cell selectionEuropean Journal of Immunology
2018 405 0
Biological agents in the management of adult-onset Still's diseaseJoint, Bone, Spine
2018 412 386
Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaborationAnnals of the Rheumatic Diseases
2018 459 1
Inflammasome Adaptor ASC Suppresses Apoptosis of Gastric Cancer Cells by an IL18-Mediated Inflammation-Independent MechanismCancer Research
2018 416 0
Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registriesRMD Open
2018 354 181
Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in miceBlood
2018 465 2
Regulation and function of interleukin-36 cytokinesImmunological Reviews
2018 473 0
Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET studyRMD Open
2018 429 198
β Cell-Specific Deletion of the IL-1 Receptor Antagonist Impairs β Cell Proliferation and Insulin SecretionCell Reports
2018 607 316
Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndromeBlood
2018 374 1
Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's diseaseAnnals of the Rheumatic Diseases
2018 539 363
Comparison of Serological Biomarkers in Rheumatoid Arthritis and Their Combination to Improve Diagnostic PerformanceFrontiers in Immunology
2018 431 336
Incidence and prevalence of major adverse cardiovascular events in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritisArthritis Care and Research
2018 438 443
Nanocrystal-Polymer Particles: Extended Delivery Carriers for Osteoarthritis TreatmentSmall
2018 646 411
The perioperative use of synthetic and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritisSwiss Medical Weekly
2017 584 436
Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritisRheumatology
2017 551 5
The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritisClinical Rheumatology
2017 632 3
Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibitionJournal of Allergy and Clinical Immunology
2017 445 2
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 updateAnnals of the Rheumatic Diseases
2017 483 2
International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosusAutoimmunity Reviews
2017 409 1
Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trialsRMD Open
2017 391 243
Cardiovascular risk in patients with rheumatoid arthritisSeminars in Immunopathology
2017 459 0
Rheumatoid arthritis: from basic findings and clinical manifestations to future therapiesSeminars in Immunopathology
2017 354 0
Granzyme A Contributes to Inflammatory Arthritis in Mice Through Stimulation of OsteoclastogenesisArthritis and Rheumatology
2017 547 0
Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA CollaborationJournal of Rheumatology
2017 435 1
Salt-inducible kinases (SIK) inhibition reduces RANKL-induced osteoclastogenesisPLOS ONE
2017 562 213
Presence of IL-17 in synovial fluid identifies a potential inflammatory osteoarthritic phenotypePloS one
2017 561 347
IL-38 overexpression induces anti-inflammatory effects in mice arthritis models and in human macrophages in vitroAnnals of the Rheumatic Diseases
2017 436 0
Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumabRMD Open
2017 394 329
The role of female hormonal factors in the development of rheumatoid arthritisRheumatology
2017 468 0
Deficiency in IL-1 Receptor Type 2 Aggravates K/BxN Serum Transfer-Induced Arthritis in Mice but Has No Impact on Systemic Inflammatory ResponsesJournal of Immunology
2017 761 2
The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial SpondyloarthritisArthritis & rheumatology
2016 532 0
A specific anti-citrullinated protein antibody profile identifies a group of rheumatoid arthritis patients with a toll-like receptor 4-mediated diseaseArthritis Research and Therapy
2016 1,066 346
Distinct expression of interleukin (IL)-36α, β and γ, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's diseaseClinical and experimental immunology
2016 548 2
Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritisAnnals of the rheumatic diseases
2016 563 243
Interleukin-36 potently stimulates human M2 macrophages, Langerhans cells and keratinocytes to produce pro-inflammatory cytokinesCytokine
2016 531 1
Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative studyAnnals of the rheumatic diseases
2016 529 0
Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritisRheumatology
2016 527 0
IL-1R1-MyD88 axis elicits papain-induced lung inflammationEuropean Journal of Immunology
2016 574 0
IL-36-Induced Toxicity in Neonatal Mice Involves TNF-α Production by Liver Myeloid CellsJournal of Immunology
2016 555 2
Elevated serum levels of free interleukin-18 in adult-onset Still's diseaseRheumatology
2016 560 0
SIK inhibition in human myeloid cells modulates TLR and IL-1R signaling and induces an anti-inflammatory phenotypeJournal of leukocyte biology
2016 515 1
Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaborationArthritis Research and Therapy
2016 500 242
Effect of particle size on the biodistribution of nano- and microparticles following intra-articular injection in miceInternational journal of pharmaceutics
2016 882 4
The interleukin (IL)-1 cytokine family--Balance between agonists and antagonists in inflammatory diseasesCytokine
2015 330 0
Limited Contribution of IL-36 versus IL-1 and TNF Pathways in Host Response to Mycobacterial InfectionPloS one
2015 563 277
Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management RegistryRheumatology
2015 501 0
Atherosclerosis severity is not affected by a deficiency in IL-33/ST2 signalingImmunity, inflammation and disease
2015 1,195 209
The dermatologists' role in managing psoriatic arthritis: results of a Swiss Delphi exercise intended to improve collaboration with rheumatologistsDermatology
2015 464 0
Severe Neutrophil-Dominated Inflammation and Enhanced Myelopoiesis in IL-33-Overexpressing CMV/IL33 MiceThe Journal of immunology
2015 679 2
Pneumococcal polysaccharide vaccination in adults undergoing immunosuppressive treatment for inflammatory diseases--a longitudinal studyArthritis research & therapy
2015 547 558
Inflammatory Articular Disease in Patients with Inflammatory Bowel Disease: Result of the Swiss IBD Cohort StudyInflammatory bowel diseases
2015 494 0
Intra-articular bioactivity of a p38 MAPK inhibitor and development of an extended-release systemEuropean journal of pharmaceutics and biopharmaceutics
2015 679 4
Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeuticsArthritis research & therapy
2014 571 450
Immune-mediated experimental arthritis in IL-33 deficient miceCytokine
2014 676 0
Inflammation: IL-36 has proinflammatory effects in skin but not in jointsNature reviews. Rheumatology
2014 585 0
Adipokines correlate with pain in lower limb osteoarthritis: different associations in hip and kneeInternational orthopaedics
2014 583 0
Joint damage progression in patients with rheumatoid arthritis in clinical remission. Do biologics perform better than synthetic antirheumatic drugs?Journal of rheumatology
2014 527 0
Traitement de fond de la polyarthrite rhumatoïdeRevue médicale suisse
2014 295 2
Biological agents in monotherapy for the treatment of rheumatoid arthritisSchweizerische medizinische Wochenschrift
2014 606 2
In Black Africans with rheumatoid arthritis, ACPA recognize citrullinated fibrinogen and the derived peptides α36-50Cit38,42 and β60-74Cit60,72,74, like in CaucasiansClinical immunology
2014 622 1
Efficacy of intra-articular bevacizumab for relapsing diffuse-type giant cell tumourAnnals of the rheumatic diseases
2014 664 2
Myeloid-related proteins 8 and 14 contribute to monosodium urate monohydrate crystal-induced inflammation in goutArthritis & rheumatology
2014 710 0
The severity of experimental arthritis is independent of IL-36 receptor signalingArthritis research & therapy
2013 632 286
Mouse neutrophils express the decoy type 2 interleukin-1 receptor (IL-1R2) constitutively and in acute inflammatory conditionsJournal of leukocyte biology
2013 550 553
Reply to Xie et al. about the article "Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis"Joint bone spine
2013 570 0
Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statementAnnals of the rheumatic diseases
2013 700 524
Hand osteoarthritis: new insightsJoint bone spine
2013 647 0
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditionsAnnals of the rheumatic diseases
2013 618 410
Tocilizumab versus adalimumab for rheumatoid arthritis - Authors' replyLancet
2013 525 0
Disease severity in K/BxN serum transfer-induced arthritis is not affected by IL-33 deficiencyArthritis research & therapy
2013 647 294
Recommendations for the use of ultrasound in rheumatoid arthritis: literature review and SONAR score experienceSchweizerische medizinische Wochenschrift
2013 833 458
Do synovial leptin levels correlate with pain in end stage arthritis?International orthopaedics
2013 679 228
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trialLancet
2013 653 0
The Activity of CCL18 is Principally Mediated through Interaction with GlycosaminoglycansFrontiers in immunology
2013 597 365
Endogenous IL-1α is a chromatin-associated protein in mouse macrophagesCytokine
2013 642 1
Coexistence of seropositive rheumatoid arthritis and SAPHO syndromeJoint bone spine
2013 641 0
Adalimumab in acute sciatica reduces the long-term need for surgery: a 3-year follow-up of a randomised double-blind placebo-controlled trialAnnals of the rheumatic diseases
2012 675 0
Long-term amelioration of established collagen-induced arthritis achieved with short-term therapy combining anti-CD3 and anti-tumor necrosis factor treatmentsArthritis and rheumatism
2012 626 1
Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonistsAnnals of the rheumatic diseases
2012 567 434
Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritisJoint bone spine
2012 753 836
Evaluation of cardiovascular risk in patients with rheumatoid arthritis: do cardiovascular biomarkers offer added predictive ability over established clinical risk scores?Arthritis care & research
2012 698 0
Mice deficient in hepatocyte-specific IL-1Ra show delayed resolution of concanavalin A-induced hepatitisEuropean Journal of Immunology
2012 624 3
The mouse interleukin (Il)33 gene is expressed in a cell type- and stimulus-dependent manner from two alternative promotersJournal of leukocyte biology
2012 714 0
Investigation of Caucasian rheumatoid arthritis susceptibility loci in African patients with the same diseaseArthritis research & therapy
2012 716 384
IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cellsBlood
2012 883 1,061
Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaborationAnnals of the rheumatic diseases
2012 618 1
EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid ArthritisAnnals of the rheumatic diseases
2012 703 583
Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patientsAnnals of the rheumatic diseases
2012 682 0
Articular inflammation is controlled by myeloid cell-derived interleukin 1 receptor antagonist during the acute phase of arthritis in miceAnnals of the rheumatic diseases
2012 679 0
Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipientsHaematologica
2011 1,054 652
Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registriesAnnals of the rheumatic diseases
2011 546 0
IL-36R ligands are potent regulators of dendritic and T cellsBlood
2011 661 0
Spontaneous secretion of interleukin-17 and -22 by human cervical cells in Chlamydia trachomatis infectionMicrobes and infection
2011 617 0
Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial at a single centerArthritis and rheumatism
2011 689 0
Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center studyArthritis and rheumatism
2011 881 8
IL-33 biology with potential insights into human diseasesNature reviews. Rheumatology
2011 612 0
Absence of up-regulation for a proliferation-inducing ligand in Sjögren's sialadenitis lesionsRheumatology
2011 679 1
The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort studyRheumatology
2011 610 0
Autoimmunity and inflammation are independent of class II transactivator type PIV-dependent class II major histocompatibility complex expression in peripheral tissues during collagen-induced arthritisArthritis and rheumatism
2011 649 0
Polyarthrite rhumatoïde,méthotrexate et fibrose pulmonaire : quelles évidences ?Revue médicale suisse
2010 850 1
Serum lipoproteins attenuate macrophage activation and Toll-Like Receptor stimulation by bacterial lipoproteinsBMC immunology
2010 602 508
Distinct roles of hepatocyte- and myeloid cell-derived IL-1 receptor antagonist during endotoxemia and sterile inflammation in miceThe Journal of immunology
2010 568 0
Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonistsJoint bone spine
2010 718 0
Enhanced Th1 and Th17 responses and arthritis severity in mice with a deficiency of myeloid cell-specific interleukin-1 receptor antagonistArthritis and rheumatism
2010 620 0
Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patientsJoint bone spine
2010 620 0
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsAnnals of the rheumatic diseases
2010 679 0
Diagnostic value of anti-cyclic citrullinated peptides and association with HLA-DRB1 shared epitope alleles in African rheumatoid arthritis patientsArthritis research & therapy
2010 794 577
Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritisArthritis and rheumatism
2010 908 3
IL-1 pathways in inflammation and human diseasesNature reviews. Rheumatology
2010 745 1
The effect of alcohol on radiographic progression in rheumatoid arthritisArthritis and rheumatism
2010 598 0
Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?Annals of the rheumatic diseases
2010 598 0
Adalimumab in severe and acute sciatica: a multicenter, randomized, double-blind, placebo-controlled trialArthritis and rheumatism
2010 677 0
Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritisArthritis and rheumatism
2009 660 0
Clinical experience with mycophenolate mofetil in systemic autoimmune conditions refractory to common immunosuppressive therapiesSchweizerische medizinische Wochenschrift
2009 635 394
Non-infectious lupus pericarditis: a retrospective hospital-based observation in Yaounde-CameroonClinical rheumatology
2009 603 0
Magnetically retainable microparticles for drug delivery to the joint: efficacy studies in an antigen-induced arthritis model in miceArthritis research & therapy
2009 805 836
Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritisArthritis and rheumatism
2009 628 0
Mutations in the IL1RN locus lead to autoinflammationNature reviews. Rheumatology
2009 583 0
Relationship between gamma-interferon and interleukin-17 in Chlamydia trachomatis reactive arthritisClinical and Experimental Rheumatology
2009 580 0
Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failureJoint bone spine
2009 575 0
The biological and clinical importance of the 'new generation' cytokines in rheumatic diseasesArthritis research & therapy
2009 608 212
Adaptive immune response in JAM-C-deficient mice: normal initiation but reduced IgG memoryThe Journal of immunology
2009 875 0
The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based studyAnnals of the rheumatic diseases
2009 612 0
Interleukin-33 is biologically active independently of caspase-1 cleavageThe Journal of biological chemistry
2009 685 531
Synovial tissues concentrate secreted APRILArthritis research & therapy
2009 668 388
The proinflammatory cytokine response to Chlamydia trachomatis elementary bodies in human macrophages is partly mediated by a lipoprotein, the macrophage infectivity potentiator, through TLR2/TLR1/TLR6 and CD14The Journal of immunology
2008 631 0
Is tocilizumab a good therapeutic option for RA and systemic-onset juvenile idiopathic arthritis?Nature reviews. Rheumatology
2008 595 0
IL-1, IL-18, and IL-33 families of cytokinesImmunological reviews
2008 914 3,881
Elevated levels of tumor necrosis factor-alpha in periradicular fat tissue in patients with radiculopathy from herniated discSpine
2008 678 0
Impaired counter-regulation of interleukin-1 by the soluble IL-1 receptor type II in patients with chronic liver diseaseScandinavian journal of gastroenterology
2008 648 0
The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33Cytokine
2008 714 0
At the horizon of innovative therapy in rheumatology: new biologic agentsCurrent opinion in rheumatology
2008 630 0
Molecular Characterization and Subcellular Localization of Macrophage Infectivity Potentiator, a Chlamydia trachomatis LipoproteinJournal of Bacteriology
2007 780 730
Expression and function of junctional adhesion molecule-C in human and experimental arthritisArthritis research & therapy
2007 653 347
Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cellsCytokine
2007 525 0
B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agentsArthritis and rheumatism
2007 178 1
Leukocyte migration to rheumatoid joints: Enzymes take overArthritis and rheumatism
2006 602 1
Henoch Schönlein purpura following etanercept treatment of rheumatoid arthritisClinical and Experimental Rheumatology
2006 546 0
The new IL-1 family member IL-1F8 stimulates production of inflammatory mediators by synovial fibroblasts and articular chondrocytesArthritis research & therapy
2006 585 335
Intracellular interleukin-1 receptor antagonist type 1 antagonizes the stimulatory effect of interleukin-1 alpha precursor on cell motilityCytokine
2005 540 489
Delayed resolution of acute inflammation during zymosan-induced arthritis in leptin-deficient miceArthritis research & therapy
2004 488 182
Total hip prosthetic joint infection due to Veillonella speciesJoint bone spine
2004 642 0
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack